[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100329618":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":38,"centralContacts":51,"locations":60,"responsibleParty":389,"collaborators":38,"id":391,"slug":392,"hasResults":393,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":38,"eligibilityCriteria":397,"healthyVolunteers":393,"sex":398,"minAge":399,"maxAge":38,"enrollmentInfo":400,"targetDuration":38,"studyType":403,"phases":404,"briefSummary":407,"conditions":408,"keywords":38,"overallStatus":77,"whyStopped":38,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":419},{"fullName":5,"class":6},"BioInvent International AB","INDUSTRY",[8,15,19,23,28],{"label":9,"type":10,"description":11,"interventionNames":12},"BI-1206 IV Dose Escalation","EXPERIMENTAL","Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab",[13,14],"Biological: BI-1206","Biological: Rituximab",{"label":16,"type":10,"description":17,"interventionNames":18},"BI-1206 SC Dose Escalation","Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Phase 2a IV Dose expansion","BI-1206 IV in Combination with Rituximab",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Phase 2a SC Signal seeking","SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib",[13,14,27],"Biological: Acalabrutinib",{"label":29,"type":10,"description":30,"interventionNames":31},"Phase 2a IV Signal Seeking","IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib",[13,14,27],[33,39,45],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"BIOLOGICAL","BI-1206","BI-1206 150 mg \u002F 225 mg Subcutaneous injection\n\nBI-1206 50 mg \u002F100 mg Intravenous infusion",[9,16,20,29,24],null,{"type":34,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Rituximab","Rituximab 375 mg\u002Fm2, as per SmPC",[9,16,20,29,24],[44],"Ruxience",{"type":34,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"Acalabrutinib","Acalabrutinib 100 mg orally as per SmPC",[29,24],[50],"Calquence",[52,57],{"name":53,"role":54,"phone":55,"phoneExt":38,"email":56},"Erika Bågeman","CONTACT","+46706126618","erika.bageman@bioinvent.com",{"name":58,"role":54,"phone":38,"phoneExt":38,"email":59},"Andres McAllister, MD, PhD","andres.mcallister@bioinvent.com",[61,75,90,107,122,136,150,164,174,185,195,205,215,231,240,252,260,276,288,298,308,321,332,342,355,369,380],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":38},"Emory University Hospital","ACTIVE_NOT_RECRUITING","Atlanta","Georgia","30322","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-84.38798,33.749,{"lat":73,"lon":72},{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":67,"countryCode":68,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405","RECRUITING","Louisville","Kentucky","40207",{"type":70,"coordinates":82},[83,84],-85.75941,38.25424,{"lat":84,"lon":83},[87],{"name":88,"role":89,"phone":38,"phoneExt":38,"email":38},"Don Stevens, MD","PRINCIPAL_INVESTIGATOR",{"facility":91,"status":77,"city":92,"state":93,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Hospital São Rafael","Salvador","Estado de Bahia","Brazil","BR",{"type":70,"coordinates":97},[98,99],-38.49096,-12.97563,{"lat":99,"lon":98},[102,105],{"name":103,"role":54,"phone":38,"phoneExt":38,"email":104},"Cacilda","analuziaschriefer@gmail.com",{"name":106,"role":89,"phone":38,"phoneExt":38,"email":38},"Ana Luiza Schriefer, MD",{"facility":108,"status":77,"city":109,"state":110,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Hospital de Clínicas de Porto Alegre","Porto Alegre","Rio Grande do Sul",{"type":70,"coordinates":112},[113,114],-51.23019,-30.03283,{"lat":114,"lon":113},[117,120],{"name":118,"role":54,"phone":38,"phoneExt":38,"email":119},"Suellen","fogliattopesquisa@gmail.com",{"name":121,"role":89,"phone":38,"phoneExt":38,"email":38},"Laura Maria Fogliatto, MD",{"facility":123,"status":124,"city":125,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer","NOT_YET_RECRUITING","Curitiba",{"type":70,"coordinates":127},[128,129],-49.27306,-25.42778,{"lat":129,"lon":128},[132,134],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":133},"munhoz.ec@gmail.com",{"name":135,"role":89,"phone":38,"phoneExt":38,"email":38},"Eduardo Munhoz, MD",{"facility":137,"status":124,"city":138,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Ruschel Medicina e Pesquisa Clínica","Rio de Janeiro",{"type":70,"coordinates":140},[141,142],-43.18223,-22.90642,{"lat":142,"lon":141},[145,148],{"name":146,"role":54,"phone":38,"phoneExt":38,"email":147},"Thaiane Alexandre, RN","thaianealexandre@ruschelmedicina.com.br",{"name":149,"role":89,"phone":38,"phoneExt":38,"email":38},"Rony Schaffel, MD",{"facility":151,"status":77,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"A.C. Camargo Cancer Center","São Paulo",{"type":70,"coordinates":154},[155,156],-46.63611,-23.5475,{"lat":156,"lon":155},[159,162],{"name":160,"role":54,"phone":38,"phoneExt":38,"email":161},"RN","ana.cordeiro@accamargo.org.br",{"name":163,"role":89,"phone":38,"phoneExt":38,"email":38},"Ana Costa Cordeiro, MD",{"facility":165,"status":124,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":166,"geoPoint":168,"contacts":169},"Hospital Amaral Carvalho",{"type":70,"coordinates":167},[155,156],{"lat":156,"lon":155},[170,172],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":171},"pesquisafac.edersonmattos@gmail.com",{"name":173,"role":89,"phone":38,"phoneExt":38,"email":38},"Ederson Roberto De Mattos, MD",{"facility":175,"status":124,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":176,"geoPoint":178,"contacts":179},"Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo",{"type":70,"coordinates":177},[155,156],{"lat":156,"lon":155},[180,183],{"name":181,"role":54,"phone":38,"phoneExt":38,"email":182},"Camila Hinsching, RN","camila.f@hc.fm.usp.br",{"name":184,"role":89,"phone":38,"phoneExt":38,"email":38},"Juliana Pereira, MD",{"facility":186,"status":77,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":187,"geoPoint":189,"contacts":190},"Hospital Israelita Albert Einstein",{"type":70,"coordinates":188},[155,156],{"lat":156,"lon":155},[191,193],{"name":160,"role":54,"phone":38,"phoneExt":38,"email":192},"guiperini@gmail.com",{"name":194,"role":89,"phone":38,"phoneExt":38,"email":38},"Guilherme Perini, MD",{"facility":196,"status":124,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":197,"geoPoint":199,"contacts":200},"Hospital Samaritano",{"type":70,"coordinates":198},[155,156],{"lat":156,"lon":155},[201,203],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":202},"carlos.chiattone@terra.com.br",{"name":204,"role":89,"phone":38,"phoneExt":38,"email":38},"Carlos Chiattone, MD",{"facility":206,"status":124,"city":152,"state":38,"zip":38,"country":94,"countryCode":95,"cosmosGeoPoint":207,"geoPoint":209,"contacts":210},"Hospital Sírio-Libanês",{"type":70,"coordinates":208},[155,156],{"lat":156,"lon":155},[211,213],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":212},"anaritafonsecabm@gmail.com",{"name":214,"role":89,"phone":38,"phoneExt":38,"email":38},"Ana Rita Da Fonseca, MD",{"facility":216,"status":124,"city":217,"state":218,"zip":38,"country":219,"countryCode":220,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Krankenhaus Nordwest Klinik für Onkologie und Hämatologie","Frankfurt am Main","Hesse","Germany","DE",{"type":70,"coordinates":222},[223,224],8.68417,50.11552,{"lat":224,"lon":223},[227,229],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":228},"weidmann.eckhart@khnw.de",{"name":230,"role":89,"phone":38,"phoneExt":38,"email":38},"Eckhart Weidmann, MD",{"facility":232,"status":233,"city":234,"state":38,"zip":38,"country":219,"countryCode":220,"cosmosGeoPoint":235,"geoPoint":239,"contacts":38},"Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care","WITHDRAWN","Stuttgart",{"type":70,"coordinates":236},[237,238],9.17702,48.78232,{"lat":238,"lon":237},{"facility":241,"status":242,"city":243,"state":38,"zip":244,"country":245,"countryCode":246,"cosmosGeoPoint":247,"geoPoint":251,"contacts":38},"Szpital Specjlistyczny","TERMINATED","Grudziądz","86-300","Poland","PL",{"type":70,"coordinates":248},[249,250],18.75366,53.48411,{"lat":250,"lon":249},{"facility":253,"status":242,"city":254,"state":38,"zip":38,"country":245,"countryCode":246,"cosmosGeoPoint":255,"geoPoint":259,"contacts":38},"Małopolskie Centrum Medyczne","Krakow",{"type":70,"coordinates":256},[257,258],19.93658,50.06143,{"lat":258,"lon":257},{"facility":261,"status":77,"city":262,"state":263,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":266,"geoPoint":270,"contacts":271},"Hospital ICO, Trias i Pujol","Badalona","Barcelona","Spain","ES",{"type":70,"coordinates":267},[268,269],2.24741,41.45004,{"lat":269,"lon":268},[272,274],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":273},"jsancho@iconcologia.net",{"name":275,"role":89,"phone":38,"phoneExt":38,"email":38},"Juan Manuel Sancho Cia, MA",{"facility":277,"status":77,"city":263,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"Hospital de la Santa Creu i Sant Pau, Dep Hematologia",{"type":70,"coordinates":279},[280,281],2.15899,41.38879,{"lat":281,"lon":280},[284,286],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":285},"smiqueleiz@santpau.cat",{"name":287,"role":89,"phone":38,"phoneExt":38,"email":38},"Sara Miqueleiz Alamos, MD",{"facility":289,"status":77,"city":263,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":290,"geoPoint":292,"contacts":293},"Hospital Universitari Vall d'Hebron",{"type":70,"coordinates":291},[280,281],{"lat":281,"lon":280},[294,296],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":295},"pabrisqueta@vhio.net",{"name":297,"role":89,"phone":38,"phoneExt":38,"email":38},"Pablo Abrisqueta Costa, MD",{"facility":299,"status":77,"city":263,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":300,"geoPoint":302,"contacts":303},"Institut Català d'Oncologia, L'Hospitalet de Llobregat",{"type":70,"coordinates":301},[280,281],{"lat":281,"lon":280},[304,306],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":305},"edomingo@iconcologia.net",{"name":307,"role":89,"phone":38,"phoneExt":38,"email":38},"Eva Domingo Domenech, MD",{"facility":309,"status":77,"city":310,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":311,"geoPoint":315,"contacts":316},"Hospital General Universitario Gregorio Marañon-Oncología Médica","Madrid",{"type":70,"coordinates":312},[313,314],-3.70256,40.4165,{"lat":314,"lon":313},[317,319],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":318},"bastosmariana@yahoo.com",{"name":320,"role":89,"phone":38,"phoneExt":38,"email":38},"Mariana Bastos Oreiro, MD",{"facility":322,"status":77,"city":310,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":323,"geoPoint":325,"contacts":326},"Hospital Universitario HM Sanchinarro",{"type":70,"coordinates":324},[313,314],{"lat":314,"lon":313},[327,330],{"name":328,"role":54,"phone":38,"phoneExt":38,"email":329},"Agustín Penedo Coello","apenedo@hmhospitales.com",{"name":331,"role":89,"phone":38,"phoneExt":38,"email":38},"Augustin Penedo Coello, MD",{"facility":333,"status":77,"city":310,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":334,"geoPoint":336,"contacts":337},"University Hospital Fundacion Jimenez Diaz",{"type":70,"coordinates":335},[313,314],{"lat":314,"lon":313},[338,340],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":339},"raul.cordoba@fjd.es",{"name":341,"role":89,"phone":38,"phoneExt":38,"email":38},"Raul Cordoba Mascunano, MD",{"facility":343,"status":124,"city":344,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":345,"geoPoint":349,"contacts":350},"Hospital Universitario Virgen de la Arrixaca","Murcia",{"type":70,"coordinates":346},[347,348],-1.13004,37.98704,{"lat":348,"lon":347},[351,353],{"name":38,"role":54,"phone":38,"phoneExt":38,"email":352},"joaquingomezespuch@hotmail.com",{"name":354,"role":89,"phone":38,"phoneExt":38,"email":38},"Joaquin Gomez Espuch, MD",{"facility":356,"status":77,"city":357,"state":38,"zip":38,"country":264,"countryCode":265,"cosmosGeoPoint":358,"geoPoint":362,"contacts":363},"Hospital University Virgen Macarene","Seville",{"type":70,"coordinates":359},[360,361],-5.97317,37.38283,{"lat":361,"lon":360},[364,367],{"name":365,"role":54,"phone":38,"phoneExt":38,"email":366},"Sergio Ortegón Alcaide","sortegonalcaide@gmail.com",{"name":368,"role":89,"phone":38,"phoneExt":38,"email":38},"Sergio Ortegon Alcaide, MD",{"facility":370,"status":242,"city":371,"state":38,"zip":372,"country":373,"countryCode":374,"cosmosGeoPoint":375,"geoPoint":379,"contacts":38},"Department of Oncology, Skåne University Hospital","Lund","SE-22185","Sweden","SE",{"type":70,"coordinates":376},[377,378],13.19321,55.70584,{"lat":378,"lon":377},{"facility":381,"status":242,"city":382,"state":38,"zip":383,"country":373,"countryCode":374,"cosmosGeoPoint":384,"geoPoint":388,"contacts":38},"Department of Oncology, Academical Hospital","Uppsala","751 85",{"type":70,"coordinates":385},[386,387],17.63889,59.85882,{"lat":387,"lon":386},{"type":390,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100329618","phase-1-a-study-of-bi-1206-in-combination-with-rituximab-with-or-without-acalabrutinib-in-subjects-with-indolent-b-cell-nhl-100329618",false,"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","Phase 1\u002F2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab","Inclusion Criteria:\n\n1. Are ≥ 18 years of age by initiation of study treatment.\n2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)\n3. Have measurable nodal disease\n4. Are willing to undergo lymph node biopsies or biopsies of other involved tissue\n5. Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists\n6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen\n7. Have a life expectancy of at least 12 weeks\n8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n9. Have CD20+ malignancy\n10. Have hematological and biochemical indices within prespecified ranges\n\nExclusion Criteria:\n\n1. Have had an allogenic bone marrow or stem cell transplant within 12 months\n2. Have presence of active chronic graft versus host disease\n3. Have current leptomeningeal lymphoma or compromise of the central nervous system\n4. Have transformed lymphoma from a pre-existing indolent lymphoma\n5. Have Waldenstrom's Macroglobulinemia or FL grade 3B,\n6. Need systemic doses of prednisolone \\>10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.\n7. Have known or suspected hypersensitivity to rituximab or BI-1206\n8. Have cardiac or renal amyloid light-chain amyloidosis\n9. Have received any of the following:\n\n   1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206\n   2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks\n   3. Immunotherapy within 8 weeks\n   4. Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib\n10. Have ongoing toxic manifestations of previous treatments.\n11. Have the ability to become pregnant (or already pregnant or lactating\u002Fbreastfeeding).\n12. Have had major surgery from which the subject has not yet recovered.\n13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.\n14. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).\n15. Have an active, known or suspected autoimmune disease.\n16. Have concurrent congestive heart failure, prior history of class III\u002F IV cardiac disease (New York Heart Association \\[NYHA\\])\n17. Have current malignancies of other types","ALL","18 Years",{"count":401,"type":402},140,"ESTIMATED","INTERVENTIONAL",[405,406],"PHASE1","PHASE2","Phase 1\u002F2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab",[409],"Indolent B-Cell Non-Hodgkin Lymphoma","2025-04-23",{"date":412,"type":413},"2025-04-24","ACTUAL",{"date":415,"type":413},"2018-05-16",{"date":417,"type":402},"2026-09-30",{"name":5,"class":6},27]